Tranilast, an FDA-approved antiallergic medication recently identified as an NLRP3 inhibitor, offers immediate repurposing opportunities for COPD management, though its relatively weak inhibitory potency may limit therapeutic efficacy in advanced disease stages (94). Here, NLRP3 is linked to chronic obstructive pulmonary disease.